Healthcare, Pharma & Life Sciences

T-MAXIMUM's Allogeneic CAR-T Shows 80% Tumor Shrinkage in Brain Metastases

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.

VIO Med Spa Signs Three-Unit Deal to Enter Charleston Market

Image
VIO Med Spa Signs Three-Unit Deal to Enter Charleston Market

CHARLESTON, S.C. – – September 21, 2026 -- VIO Med Spa has signed a three-unit development agreement to enter South Carolina for the first time, with the first Charleston-area location targeted to open in 2027. Site selection is currently underway.

Former CVS Health Executive Leads Local Development

Ted Loya, who spent more than 23 years at CVS Health in its pharmacy benefits business working with national employers, will spearhead the brand's build-out across the Charleston area. New to franchising and medical aesthetics, Loya cited VIO's established infrastructure, financial backing, and existing East Coast footprint in North Carolina and Georgia as deciding factors in bringing the brand to South Carolina.

Deal Extends Brand's East Coast Footprint

Ryan Rao, Chief Development Officer at VIO Med Spa, said the Charleston entry strengthens the company's presence in the Southeast and supports further expansion along the East Coast.

Ernest Health Secures Sites for 6 NC Rehab Hospitals

Image
Ernest Health Secures Sites for 6 NC Rehab Hospitals

Mesquite, Texas – September 21, 2026 -- Ernest Health has secured development sites in six North Carolina markets for freestanding inpatient rehabilitation hospitals, marking Phase 1 of a statewide expansion program. The company controls parcels in Winston-Salem, Mooresville, Gastonia, Hickory, South Asheville/Arden and Goldsboro through development partner Summit Healthcare Group.

Six sites move from announcement to construction-ready status

Summit Healthcare Group, a Winston-Salem-based healthcare real estate firm founded in 2008 with more than 750,000 square feet of ground-up healthcare delivery experience, now holds control of all six parcels. The sites span the Piedmont Triad, the Lake Norman and Gaston County submarkets of Charlotte, the Catawba Valley, Western North Carolina and Eastern North Carolina. Each location was chosen for proximity to acute care referral sources, transportation access and local older-adult population density.

Scinai Regains Nasdaq Compliance on $1.00 Minimum Bid Price Rule

Image
Scinai Regains Nasdaq Compliance on $1.00 Minimum Bid Price Rule

Jerusalem – September 21, 2026 -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after its American Depositary Shares closed at or above that threshold for 19 consecutive business days, Nasdaq Listing Qualifications confirmed in a September 18, 2026 letter.

Nasdaq closes compliance matter after ADS price clears threshold for 19 sessions

The closing bid price of Scinai's ADSs met or exceeded $1.00 per share from August 21, 2026 through September 17, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). Nasdaq had first flagged the deficiency on March 12, 2026, after the ADSs failed to maintain the $1.00 minimum over the prior 30 consecutive business days.

CEO says resolution shifts focus to CDMO commercial execution

"Receiving Nasdaq's confirmation closes an important compliance matter for Scinai,

FDA Grants Priority Review to Insmed's ARIKAYCE Full Approval Bid

Image
FDA Grants Priority Review to Insmed's ARIKAYCE Full Approval Bid

Bridgewater, N.J. – September 21, 2026 -- The U.S. Food and Drug Administration has accepted Insmed Incorporated's supplemental New Drug Application (sNDA) for full approval of ARIKAYCE (amikacin liposome inhalation suspension) to treat Mycobacterium avium complex (MAC) lung disease, granting Priority Review with a PDUFA target action date of January 28, 2027.

FDA sets January 28, 2027 decision date under Priority Review

The Priority Review designation applies to therapies that could offer significant improvement in safety or efficacy for serious conditions. Insmed said full approval would allow ARIKAYCE, administered via PARI Pharma's Lamira Nebulizer System, to reach patients earlier in their disease course, including newly diagnosed cases and those with recurrent infections.

FDA Grants Platform Designation to Precigen's AdenoVerse Tech

Image
FDA Grants Platform Designation to Precigen's AdenoVerse Tech

Germantown, Md. – September 21, 2026 -- The U.S. Food and Drug Administration has granted platform technology designation to Precigen's AdenoVerse immunotherapeutic platform, the technology underlying the company's first commercial product, PAPZIMEOS, approved in August 2025 for recurrent respiratory papillomatosis (RRP) in adults.

FDA designation opens accelerated pathway for future AdenoVerse cancer programs

The designation allows Precigen to leverage manufacturing and preclinical data generated for PAPZIMEOS to support future marketing applications for other AdenoVerse-based candidates, reducing duplicative development work. It also grants the company earlier and more frequent FDA engagement and allows regulators to consider prior manufacturing inspections when reviewing future applications.

Vylor, Rainbow Crops Partner on AI-Driven Corn Gene Editing

Image
Vylor, Rainbow Crops Partner on AI-Driven Corn Gene Editing

Johnston, Iowa and Ghent, Belgium – September 21, 2026 -- Vylor, the seed and genetics company set to spin off from Corteva on October 1, 2026, has partnered with Belgium's Rainbow Crops to develop climate-resilient corn traits using AI-driven multiplex gene editing.

Rainbow Crops' Trait Foundry platform edits hundreds of genes simultaneously

The collaboration will deploy Rainbow Crops' AI-supported Trait Foundry™ technology, which combines multiplex genome editing, precision breeding and automated phenotyping to accelerate development of corn hybrids resistant to heat, drought and flooding. Mat Muller, who will lead Vylor Edge, Vylor's investment arm, said the platform allows scientists to make hundreds of gene edits simultaneously while validating performance through phenotyping facilities and field trials.

WuXi XDC Wins GMP Release for First Overseas Site in Singapore

Image
WuXi XDC Wins GMP Release for First Overseas Site in Singapore

Singapore – September 21, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has secured GMP release for its Singapore manufacturing site at Tuas Biomedical Park, marking the bioconjugate CRDMO's first overseas facility just two and a half years after the site was announced in March 2024.

BCM3 dual-function line and DP4 drug product facility clear GMP release

The 25,000-square-meter site achieved GMP release for both its BCM3 antibody intermediate and conjugated drug substance production line and its DP4 drug product facility in August 2026. BCM3 supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances, operating under FDA, EMA and NMPA standards. A second line, BCM4, is slated for GMP release by the end of 2026 with a maximum single-batch capacity of 500 L for conjugated drug substance.

SirPAD Trial Subgroup Data on Sirolimus Balloon Set for VIVA 2026

Image
SirPAD Trial Subgroup Data on Sirolimus Balloon Set for VIVA 2026

Las Vegas – September 21, 2026 -- Concept Medical's MagicTouch sirolimus-coated balloon will face fresh scrutiny at VIVA 2026 as researchers unveil new subgroup data from the SirPAD randomized trial covering 597 patients treated for femoropopliteal peripheral artery disease without tissue loss.

SirPAD enrolled 1,252 patients to compare drug-coated and uncoated balloon angioplasty

The academic, investigator-initiated trial randomized 1,252 patients with symptomatic infrainguinal peripheral artery disease to angioplasty using either the MagicTouch PTA sirolimus-coated balloon or an uncoated balloon. Primary results, published in the New England Journal of Medicine, showed the sirolimus-coated balloon arm was both non-inferior and superior to the uncoated balloon on major adverse limb events (MALE) at one year.

Grünenthal Buys Bayer's Stivarga in Deal Worth Up to €375M

Image
Grünenthal Buys Bayer's Stivarga in Deal Worth Up to €375M

Aachen, Germany – September 21, 2026 -- Grünenthal has agreed to acquire Bayer AG's oncology drug Stivarga® (regorafenib) for up to €375 million, adding an oral cancer treatment sold in more than 90 markets to its portfolio.

Grünenthal expects Stivarga to add up to €100 million to EBITDA in 2027

The German pharmaceutical company said the acquisition is immediately accretive to its business, with an estimated positive impact on consolidated EBITDA of approximately €100 million for the year ending December 31, 2027. That projection assumes the deal closes by the end of 2026 or early 2027 and includes a full year of consolidation.